NAVLE Nervous

Equine Degenerative Myeloencephalopathy Study Guide

📅 March 28, 2026 ⏱ 25 min read

Equine neuroaxonal dystrophy (eNAD) and equine degenerative myeloencephalopathy (EDM) are inherited neurodegenerative disorders affecting the brainstem and spinal cord in horses.

Overview and Clinical Importance

Equine neuroaxonal dystrophy (eNAD) and equine degenerative myeloencephalopathy (EDM) are inherited neurodegenerative disorders affecting the brainstem and spinal cord in horses. These conditions represent a spectrum of the same disease, with EDM being the more advanced form that includes spinal cord involvement. They are among the top three causes of spinal ataxia in horses euthanized for neurologic disease and have been identified as the second most common cause of spinal cord disease at multiple veterinary teaching hospitals.

The disease is characterized by symmetric proprioceptive ataxia that typically develops in young horses between 6 to 24 months of age. The condition results from a combination of genetic susceptibility and vitamin E deficiency during critical developmental periods. Understanding this disease is essential for NAVLE preparation as it represents an important differential diagnosis for any young horse presenting with symmetric ataxia.

High-YieldOn the NAVLE, when you see a young horse (less than 2 years old) with symmetric proprioceptive ataxia, a wide-based stance, and low serum vitamin E levels, think eNAD/EDM. Remember that definitive diagnosis requires postmortem histopathology - there is NO confirmatory antemortem test.

Feature	Description
Primary Lesion	Neuraxonal dystrophy with spheroid (swollen axon) formation in brainstem nuclei and spinal cord
Affected Tracts	Spinocuneocerebellar tract, dorsal spinocerebellar tract, and ventromedial motor tracts (in severe cases)
Brainstem Nuclei	Lateral accessory cuneate nucleus (LACN), medial cuneate nucleus, gracile nucleus, and nucleus thoracicus
Histologic Findings	Axonal spheroids, neuronal chromatolysis, axonal loss, secondary demyelination, lipofuscin pigment accumulation, mild glial proliferation
Gross Pathology	No visible gross lesions at necropsy - diagnosis requires microscopic examination

Etiology and Pathophysiology

Disease Mechanism

eNAD/EDM is a neuraxonal dystrophy characterized by progressive degeneration of specific neuronal populations in the brainstem nuclei and spinal cord. The pathogenesis involves the interaction between genetic susceptibility and environmental factors, primarily vitamin E deficiency during early development.

Vitamin E (Alpha-Tocopherol) Deficiency

Alpha-tocopherol is the biologically active form of vitamin E and serves as the primary lipid-soluble antioxidant in the body. It functions to maintain normal neuromuscular function by protecting neuronal cell membranes from oxidative stress and free radical damage. Horses cannot synthesize vitamin E endogenously and must obtain it through dietary sources. Fresh green pasture is the richest natural source, containing 45 to 400 IU/kg dry matter. When hay is cut and dried, vitamin E content degrades significantly, often decreasing tenfold from fresh forage levels.

Genetic Component

Studies indicate an autosomal dominant mode of inheritance with incomplete penetrance. Research has focused on genes involved in vitamin E metabolism, particularly the alpha-tocopherol transfer protein (TTPA) gene, though this has been excluded as the causative mutation in some breeds. The genetic susceptibility appears to involve proteins that regulate vitamin E transfer and metabolism, leading to higher vitamin E turnover in affected individuals. This explains why some horses on the same diet develop clinical disease while others remain normal.

Key Pathophysiologic Features

High-YieldeNAD and EDM are clinically indistinguishable. The distinction is pathological: eNAD involves lesions primarily in the brainstem, while EDM includes additional white matter tract degeneration throughout the spinal cord. EDM is considered the more advanced form of the same disease process.

Most Commonly Affected	Also Reported In
Quarter Horses Appaloosas Morgans Lusitanos Arabians	Thoroughbreds, Standardbreds Paint Horses, Paso Finos Norwegian Fjords, Haflingers Tennessee Walking Horses Warmbloods, Gypsy Vanners

Breed Predisposition and Risk Factors

Affected Breeds

eNAD/EDM has been documented in numerous horse breeds, suggesting a widespread genetic susceptibility. Historically, the disease was first recognized in the northeastern United States, but it has since been identified worldwide.

Risk Factors

Familial history: Horses with affected siblings or parents are at significantly increased risk
Limited pasture access: Housing on dirt lots or dry lots without green forage
Hay-based diets: Without vitamin E supplementation (hay loses significant vitamin E during curing)
Environmental factors: Possible exposure to wood preservatives or insecticides (historical association)
Age at deficiency: Vitamin E deficiency during first year of life is critical for disease development
No sex predilection: Males and females equally affected (though geldings may be overrepresented in some studies)

Board Tip - Memory Aid: "EDM = Early Development Matters" - Remember that vitamin E deficiency during the FIRST YEAR of life is critical for disease development. The genetic susceptibility is present, but the environmental trigger (vitamin E deficiency) during this critical window determines if clinical disease develops.

Clinical Sign	Description
Symmetric Ataxia	General proprioceptive ataxia affecting all four limbs symmetrically; hindlimbs typically more severely affected than forelimbs; grade 2/5 or higher on Mayhew scale
Abnormal Stance	Base-wide stance at rest OR base-narrow stance with limbs positioned under the thorax; horses stand awkwardly and may appear uncomfortable
Proprioceptive Deficits	Horses do not know where their limbs are positioned; delayed protraction, circumduction (outward swing of limbs), overreaching, toe-dragging, limb interference
Hyporeflexia	Decreased or absent cutaneous trunci (panniculus) reflex; decreased cervicofacial reflex; abnormal slap test response
Behavioral Changes	Quarter Horses may be abnormally quiet and dull; some horses show altered personality, spooking, bolting, or refusing fences
Gait Abnormalities	Truncal sway, stumbling, toe-stabbing when walking uphill, difficulty with tight circles, knuckling over at fetlocks (especially downhill)

Clinical Signs and Presentation

Age of Onset and Progression

Clinical signs typically appear between 6 to 24 months of age, though some horses may show signs as early as 1 to 2 months. The onset is insidious - owners often describe the foal as "clumsy" before recognizing overt neurologic signs. Progression is variable: signs may worsen over days to months but typically stabilize by 2 to 3 years of age. Late-onset cases have also been reported in older horses (5 to 15 years), often Warmbloods, presenting initially with behavioral changes.

Cardinal Clinical Features

Grade	Clinical Description
0	Normal strength and coordination; no neurologic deficits detected
1	Subtle neurologic deficits only noted under special circumstances (walking with head elevated, tight circling, walking over obstacles, manipulative tests)
2	Mild neurologic deficits apparent at all times and gaits; horse walks like a sedated patient; more obvious response to manipulative tests
3	Moderate deficits at all times and gaits that are obvious to all observers, regardless of expertise
4	Severe deficits with tendency to buckle, stumble spontaneously, trip, and fall
5	Recumbent; unable to rise even with encouragement; may not be able to achieve sternal position

Neurologic Examination

Mayhew Ataxia Grading Scale

The Mayhew modified ataxia grading scale is used to quantify the severity of general proprioceptive (spinal) ataxia in horses. This is the standard grading system used in clinical practice and on board examinations.

Examination Maneuvers

The following maneuvers are performed to evaluate neurologic status:

Walking in a straight line: Observe for toe-dragging, overreaching, stumbling, truncal sway
Tight circles: Watch for circumduction, pivoting on inside limbs, limb interference
Head elevation while walking: Removes visual horizon; exacerbates proprioceptive deficits
Walking on inclines: Toe-stabbing uphill, knuckling/truncal ataxia downhill
Backing: Observe for delay, dragging toes, crossing limbs
Tail pull while walking: Normal horses quickly correct; ataxic horses easily pulled off balance
Walking over obstacles: Assess foot placement and mistakes
Limb placement test: Cross forelimbs or place in wide stance; assess correction speed

High-YieldRemember the classic saying: "A lame horse is regularly irregular, and an ataxic horse is irregularly irregular." Lameness produces consistent, predictable gait abnormalities, while ataxia produces random, unpredictable foot placement errors.

Key Reflex Assessment

Reflex	How to Perform	EDM Finding
Cutaneous Trunci	Prod skin along dorsum from caudal to cranial with hemostat or pen tip; observe for skin twitch	Decreased or absent; hyporeflexia increases suspicion for EDM
Cervicofacial	Tap skin between jugular groove and crest at C2 level; expect ear flick and lip retraction	May be reduced at level of cervical spinal cord lesion
Slap Test	Slap withers with moderate intensity; observe for adduction of contralateral arytenoid cartilage via endoscopy	Abnormal response suggests brainstem or cervical spinal cord disease; low sensitivity (approximately 50%)

Diagnostic Approach

Antemortem Evaluation

CRITICAL: There is NO definitive antemortem diagnostic test for eNAD/EDM. Diagnosis in the living horse is made by: (1) recognizing characteristic clinical signs, (2) ruling out other causes of spinal ataxia, and (3) identifying supportive evidence such as low serum vitamin E levels and familial history.

Diagnostic Workup

NAVLE TipPhosphorylated neurofilament heavy chain (pNfH) is an emerging biomarker for neurologic disease. It represents the first antemortem diagnostic test available for eNAD/EDM but has LOW SENSITIVITY. A serum pNfH greater than 1 ng/mL is significantly associated with eNAD/EDM diagnosis, but values below this DO NOT rule out disease.

Definitive Diagnosis

Definitive diagnosis requires postmortem histologic evaluation of the brainstem (caudal medulla) and cervicothoracic spinal cord. The pathologist looks for characteristic axonal spheroids (swollen axons), axonal loss, neuronal chromatolysis, secondary demyelination, and lipofuscin pigment accumulation in specific nuclei (lateral accessory cuneate nucleus, medial cuneate nucleus, gracile nucleus, nucleus thoracicus).

Test	Purpose	Expected Findings in EDM
Serum Vitamin E	Assess alpha-tocopherol status	May be low (less than 2 micrograms/mL suggestive) but can be NORMAL at presentation
Cervical Radiographs	Rule out cervical vertebral compressive myelopathy (CVCM)	Normal; no vertebral malformation or stenosis
Myelography/CT	Rule out spinal cord compression	No evidence of cord compression
CSF Analysis	Rule out EPM, EHV-1, Lyme disease	Typically normal cytology; negative for infectious agents
EPM Serology	Rule out Sarcocystis neurona infection	Serum/CSF antibody ratio negative for intrathecal production
pNfH Biomarker	Emerging test for axonal damage	Serum pNfH greater than 1 ng/mL is suggestive (12% sensitivity, 99% specificity); CSF greater than 3 ng/mL indicates axonal degeneration

Differential Diagnosis

Several neurologic conditions produce clinical signs similar to eNAD/EDM and must be systematically ruled out:

Board Tip - Key Differentiator: EPM = ASYMMETRIC ataxia. eNAD/EDM and CVCM = SYMMETRIC ataxia. When you see symmetric ataxia in a young horse, your top differentials are eNAD/EDM and CVCM. Radiographs rule out CVCM; if radiographs are normal, consider eNAD/EDM.

Condition	Distinguishing Features	Diagnosis
Cervical Vertebral Compressive Myelopathy (CVCM/Wobblers)	Similar symmetric ataxia; typically young, rapidly growing horses; may have cervical pain	Cervical radiographs show vertebral malformation; myelography or CT confirms cord compression
Equine Protozoal Myeloencephalitis (EPM)	ASYMMETRIC ataxia (key differentiator); focal muscle atrophy common; any age; variable progression	Serum/CSF antibody ratio testing for Sarcocystis neurona and Neospora hughesi
Equine Herpesvirus-1 Myeloencephalopathy (EHM)	Acute onset; often bladder dysfunction; may have fever, respiratory signs, or recent exposure to stressed horses	Virus isolation, PCR from nasal swab or blood; CSF xanthochromia
Cervical Trauma	History of trauma; acute onset; may have neck pain, swelling; asymmetric signs possible	Radiographs may show fracture/subluxation
Equine Motor Neuron Disease (EMND)	Generalized weakness (not ataxia); muscle atrophy; trembling; low head carriage; tail head elevation; older horses (peak 16 years)	Low vitamin E; EMG changes; muscle biopsy

Treatment and Management

Current Treatment Reality

There is NO effective treatment to reverse neurologic deficits once clinical signs of eNAD/EDM are present. Vitamin E supplementation can halt disease progression but will NOT improve existing neurologic deficits. The clinical signs typically stabilize by 2 to 3 years of age.

Vitamin E Supplementation

Prognosis

Neurologic deficits are permanent: Once clinical signs develop, they do not resolve
Stabilization typical: Signs usually stabilize by 2-3 years of age
Safety concerns: Most affected horses are unsafe to ride due to loss of proprioception
Breeding recommendation: Affected horses should NOT be bred due to genetic component
Early intervention: Foals showing early signs (before 1 year) supplemented with 6,000 IU/day appeared normal by 2 years in some studies

Parameter	Recommendation
Preferred Form	RRR-alpha-tocopherol (natural d-alpha-tocopherol) - 5x more bioavailable than synthetic dl-alpha-tocopherol
Best Formulation	Water-dispersible/micellized forms (Nano-E, Elevate WS) - superior absorption; rapidly raises serum levels within 12 hours
NRC Maintenance Dose	1-2 IU/kg body weight/day (500-1000 IU/day for 500 kg horse)
Therapeutic Dose	5,000-10,000 IU/day for horses with neurologic disease; up to 6,000 IU/day has shown benefit in young affected horses
Target Serum Level	Greater than or equal to 2 micrograms/mL (adequate); some sources suggest greater than or equal to 4 ppm as optimal
Upper Safe Limit	20 IU/kg body weight/day (10,000 IU/day for 500 kg horse); higher doses may cause coagulopathy

Prevention Strategies

Prevention is the BEST management approach for eNAD/EDM. Focus on genetically susceptible herds (those with affected family members).

Prevention Protocol for At-Risk Herds

Maintain pregnant mares on lush green pasture throughout pregnancy, especially the last trimester
Supplement pregnant mares with 5,000 IU/day of natural water-dispersible vitamin E during the last 4 months of gestation
Supplement foals with 500 IU/day (10 IU/kg) from birth; increase dose as foal grows
Continue supplementation through 2 years of age for all genetically susceptible horses
Monitor serum vitamin E levels regularly; adjust supplementation to maintain adequate levels
Perform neurologic examinations at 1 month, 6 months, and every 6 months thereafter until 2 years of age
Provide pasture access whenever possible; avoid housing on dirt lots without green forage

High-YieldSupplementing mares with 1,500 IU/day of vitamin E reduced EDM incidence in foals from 40% to 10% in one study. This emphasizes that prevention through maternal and neonatal supplementation is far more effective than treatment after clinical signs develop.

Practice NAVLE Questions

Test your knowledge with 10,000+ exam-style questions, detailed explanations, and timed exams.

Start Your Free Trial →